The stakes of this debate are unusually high. REM sleep behavior disorder, the clinical condition that arises when dream enactment accompanies loss of REM atonia, is now recognized as one of the most powerful early warning signs in all of medicine. Longitudinal cohort studies, including the landmark observational work by Alex Iranzo and colleagues published in The Lancet Neurology, followed patients diagnosed with idiopathic REM sleep behavior disorder, meaning cases with no obvious cause, and found that a large proportion went on to develop Parkinson’s disease or dementia with Lewy bodies, with post-mortem examination in some cases confirming synuclein pathology, the same protein abnormality that underlies those disorders. A subsequent multicenter study led by Ronald Postuma and an international team, published in the journal Brain, confirmed across dozens of centers that idiopathic REM sleep behavior disorder carries a substantial risk of incident dementia and parkinsonism over time. In practical terms, a polysomnography report showing REM sleep without atonia can set in motion years of anxious monitoring, counseling about future neurodegeneration, and even screening for enrollment in preventive drug trials targeting alpha-synuclein before symptoms emerge.

Into this high-stakes diagnostic arena steps a confounder that sleep clinicians have wrestled with for years: antidepressant medication. Since the early 2000s, accumulating evidence has linked the most widely prescribed antidepressants, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, with both REM sleep behavior disorder symptoms and the underlying electrophysiological abnormality of REM sleep without atonia. The mechanisms are thought to involve serotonergic and noradrenergic modulation of the brainstem circuitry that governs REM atonia, effectively interfering with the switch that paralyzes the dreaming body. Postuma and colleagues raised the central question in a 2013 paper in the journal Sleep, asking whether antidepressant-associated REM sleep behavior disorder is an isolated side effect of the drugs or a neurodegenerative signal, a medication unmasking a process that was already underway. That question has never been fully resolved, and it sits at the heart of the new letter.

The letter responds directly to a recent quantitative study by Joumana Ahdab, Claudio Rodriguez, Margaret Grigg-Damberger, and colleagues, published in the same journal, which examined how different antidepressant medications have differential effects on REM sleep without atonia when it is quantified by chin and upper extremity electromyography. That work matters because the measurement itself is not straightforward. Polysomnography scoring of REM sleep without atonia depends on which muscles are sampled, how much electrical activity is counted as excessive, and which scoring rules are applied. The chin EMG channel is the traditional standard, but abnormal movements in REM sleep behavior disorder often manifest most dramatically in the limbs, and studies have shown that adding upper extremity EMG channels can substantially increase detection. Ahdab and colleagues’ finding that specific antidepressants differ in how much they elevate muscle tone during REM sleep, and that the effect varies depending on whether chin or arm muscles are measured, adds a crucial layer of nuance to a diagnostic system that often treats REM sleep without atonia as a binary yes-or-no finding.

Munir and his coauthors use this new evidence to argue for an expanded interpretation of the phenomenon. The core of their argument is that REM sleep without atonia in an antidepressant user cannot be read through the same lens as the same finding in a medication-free patient. If different drugs push the EMG signal in different directions, and if the choice of muscle group changes the result, then a single polysomnographic reading in a person taking, say, an SSRI may reflect a pharmacological effect on brainstem motor control rather than an early degenerative process. Interpreting such a finding as automatically equivalent to idiopathic REM sleep behavior disorder risks mislabeling patients, generating unwarranted fear of impending Parkinson’s disease or dementia, and potentially steering people away from effective psychiatric treatment out of alarm about their sleep study results.

At the same time, the letter’s authors are careful not to swing the pendulum too far in the other direction, because dismissing REM sleep without atonia in antidepressant users as a harmless side effect carries its own dangers. The 2013 Postuma analysis in Sleep found evidence pointing in both directions: antidepressant-associated REM sleep behavior disorder shares features with the idiopathic form, and some researchers have proposed that the medications may act as an unmasking agent, revealing subclinical neurodegeneration that would otherwise have remained silent for years. Under this model, a person whose brainstem inhibitory circuits are already being eroded by early synuclein disease has less reserve to resist the atonia-suppressing effects of serotonergic drugs, so the medication does not create the vulnerability but exposes it. If that model is correct, then REM sleep without atonia in an antidepressant user may still be a meaningful prognostic sign, and simply attributing it to the prescription would mean missing an opportunity for early surveillance.

The practical implications for clinical practice are considerable. Sleep physicians scoring a polysomnogram currently face a genuine interpretive dilemma when the patient’s medication list includes an antidepressant. Guidelines for REM sleep behavior disorder diagnosis do not fully account for drug effects on quantitative EMG measures, and there is no established algorithm for distinguishing pharmacological REM sleep without atonia from a neurodegenerative prodrome. The letter suggests that interpretation should be broadened to incorporate the medication context explicitly: which antidepressant the patient is taking, at what dose, for how long, whether the abnormal muscle tone is confined to the chin or extends to the limbs, and whether there is actual dream enactment behavior rather than isolated EMG abnormality. A finding of elevated chin tone alone in a patient who recently started a serotonergic antidepressant and has never acted out a dream is a very different clinical entity from violent nocturnal behaviors in a long-term user with limb movements and autonomic or olfactory changes suggestive of early parkinsonism.

The letter also underscores a broader lesson about how biomarkers travel from the research laboratory into everyday medicine. Quantitative REM atonia measures were developed and validated largely in cohorts carefully selected to answer specific research questions, often excluding people taking psychotropic medications precisely because those drugs confound the signal. When those same measures are applied in routine clinical polysomnography, where antidepressant use is common and often unremarked, the interpretive framework does not automatically come along with the measurement. The Islamabad authors’ contribution is to insist that the field close this gap, developing medication-aware reference ranges and interpretive standards so that a polysomnographic number means the same thing regardless of the patient’s pharmacy. Until that happens, they argue, clinicians should treat REM sleep without atonia in antidepressant users as a finding requiring nuanced judgment rather than a fixed diagnostic verdict.

What makes this debate resonate beyond the sleep laboratory is its window into the brain’s chemistry of dreaming. The fact that a daily pill for depression can loosen the grip of the paralysis that normally binds us to the mattress is a vivid reminder that the boundary between the dreaming mind and the waking body is actively maintained by specific neurotransmitter systems, and that those systems can be nudged by the medicines we take for entirely different purposes. Whether that nudging is benign, or whether it occasionally illuminates a disease process smoldering years before its first tremor, remains one of the most consequential open questions in sleep medicine. The letter by Munir, Imran, and Faraz does not settle it, but it makes a persuasive case that the answer will not come from treating all REM sleep without atonia as one thing. As antidepressant use continues to rise worldwide and as preventive trials for synucleinopathies move closer to reality, getting this interpretation right will determine who is told to worry, who is reassured, and who is offered a genuine head start against diseases that medicine has so far only been able to diagnose too late.

Subject of Research: REM sleep without atonia in antidepressant users and its implications for REM sleep behavior disorder diagnosis

Article Title: Expanding the interpretation of REM sleep without atonia in antidepressant users

Article References: Munir, A. B., Imran, H., & Faraz, N. (2026). Expanding the interpretation of REM sleep without atonia in antidepressant users. Journal of Clinical Sleep Medicine, 22(1), Article 147. https://doi.org/10.1007/s44470-026-00167-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00167-8

Keywords: REM sleep, REM sleep behavior disorder, antidepressants, polysomnography, sleep medicine, neurodegeneration, Parkinson's disease, dementia, SSRIs, psychopharmacology, EMG, sleep disorders

The research, led by Gustavo Garrido and colleagues at the Bahiana School of Medicine and Public Health in Salvador, Brazil, followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane guidelines, and was prospectively registered in the PROSPERO database under registration number CRD42024579831. The team searched three major biomedical databases—PubMed, Embase, and the Cochrane Library—to identify studies that had examined the relationship between sleep paralysis and anxiety. After screening, eleven eligible studies encompassing a total of 5,568 participants made it into the final analysis. Study quality was appraised with the Newcastle-Ottawa Scale, a standard instrument for judging the methodological rigor of nonrandomized research, and study selection was managed using the Rayyan screening platform.

The statistical approach was deliberately conservative. Rather than pooling data with a single fixed estimate that assumes all studies measure the same underlying effect, the investigators used random-effects models estimated with restricted maximum likelihood (REML), a method that accommodates genuine variability between studies. Two complementary outcomes were examined. The first compared continuous anxiety scores between people who experience sleep paralysis and those who do not, expressed as a standardized mean difference (SMD). The second compared the prevalence of formally diagnosed anxiety disorders between the two groups, expressed as a risk ratio (RR). Heterogeneity among studies was quantified with the I-squared statistic, publication bias was assessed with funnel plots and Egger’s test, and the robustness of the pooled estimates was probed with subgroup and leave-one-out sensitivity analyses. All computations were performed in R version 4.4.1 using the metafor package, a widely respected open-source tool for meta-analytic work.

The headline result concerns anxiety symptoms. Across the pooled studies, individuals who experience sleep paralysis scored significantly higher on measures of anxiety than controls, with a standardized mean difference of 0.35 (95 percent confidence interval 0.27 to 0.44, p < 0.01). In the language of meta-analysis, an SMD of this magnitude represents a small-to-moderate but reliable effect. What makes the finding especially striking is the heterogeneity figure: I-squared was 0.0 percent, meaning the studies were in remarkable agreement despite differences in populations, instruments, and settings. In behavioral science, where pooled effects often scatter wildly, a zero heterogeneity value is rare and lends unusual confidence to the conclusion. Publication bias, the tendency for journals to favor positive findings, was judged to be low, further strengthening the result.

The picture was more nuanced for diagnosed anxiety disorders. When the prevalence of formal anxiety conditions was compared between people with and without sleep paralysis, the pooled risk ratio of 1.28 (95 percent confidence interval 0.59 to 2.77, p = 0.53) did not reach statistical significance. However, the sensitivity analysis told a different story. When a single outlying study was excluded, the estimate shifted to a risk ratio of 1.80 (95 percent confidence interval 1.08 to 2.99), indicating that people with sleep paralysis face nearly double the risk of having an anxiety disorder. The discrepancy between the primary and sensitivity analyses underscores how a single influential dataset can obscure an underlying pattern, and the authors concluded that sleep paralysis appears to occur more frequently among individuals with anxiety-related conditions even though the evidence for diagnosis-level prevalence is less consistent than the evidence for symptom levels.

Understanding why this association exists requires a brief tour of sleep neurobiology. During healthy REM sleep, the brainstem actively inhibits motor neurons, producing the near-total paralysis that prevents us from acting out our dreams. Sleep paralysis occurs when this atonia persists into a state of partial or full wakefulness during the transition between sleep and waking—either while falling asleep (hypnagogic) or upon awakening (hypnopompic). Crucially, the fear circuitry of the brain, including the amygdala, is highly active during REM sleep, and Dreaming during this stage is disproportionately negative in emotional tone. When a person regains awareness while still paralyzed, that raw, unfiltered fear state can merge with waking consciousness, producing the intense terror, chest pressure, and hallucinatory intrusions—shadowy figures, sensed presences, incubi—that define the classic episode. An anxious brain, primed to detect threat, may both experience these episodes more frequently and find them more traumatizing when they occur.

The causal arrow, however, almost certainly points in both directions. Prior research has established that anxiety disorders, post-traumatic stress disorder, panic attacks, and pathological worry are all more common among people who report sleep paralysis, and experimental work has documented objective REM-sleep abnormalities in patients with recurrent isolated sleep paralysis. Chronic anxiety disrupts sleep architecture, fragments sleep, and increases nighttime awakenings—conditions that raise the probability of a REM intrusion into wakefulness. Conversely, the episodes themselves are aversive and frightening enough to generate anticipatory fear of sleep, perpetuating insomnia and reinforcing the anxiety loop. Earlier epidemiological work has also tied sleep paralysis to depression and to poor sleep quality more broadly, and studies of high-stress occupational groups such as firefighters have reported elevated rates of the phenomenon in the context of trauma exposure.

The clinical implications of the new synthesis are tangible. Lifetime prevalence of sleep paralysis in the general population has been estimated at roughly 8 percent in earlier systematic reviews, with substantially higher rates among students and psychiatric populations, meaning the phenomenon is far from rare. Sleep medicine specialists emphasize that isolated sleep paralysis is benign in itself, but the new findings suggest that clinicians encountering patients with recurrent episodes should screen for anxiety symptoms rather than treating the parasomnia in isolation. Because the effect on anxiety scores was consistent across all included studies, even modest elevations may accumulate into meaningful distress, particularly given that anxiety disorders impose substantial burdens on quality of life worldwide and their global prevalence has been rising. Behavioral interventions—improving sleep hygiene, regularizing sleep schedules, addressing sleep deprivation, and treating underlying anxiety—may simultaneously reduce both the frequency of episodes and the emotional suffering surrounding them.

The researchers are careful to note the limitations inherent to observational synthesis. The included studies were largely cross-sectional, so the data cannot determine whether anxiety causes sleep paralysis, sleep paralysis fuels anxiety, or shared vulnerabilities—such as genetic predisposition, trauma history, or disrupted REM regulation—drive both. Self-reported sleep paralysis also depends on accurate recall and honest disclosure of an experience many people find embarrassing or frightening to describe. Still, with eleven studies, nearly 5,600 participants, zero heterogeneity in the symptom analysis, and low publication bias, the association itself now rests on a firmer statistical foundation than ever before. For the millions who wake in the small hours, frozen and afraid, the message of this research is oddly comforting: the night-mare is not a supernatural visitation but a measurable intersection of REM physiology and emotional health—and one that science is steadily learning to name, explain, and treat.

Beyond the pooled statistics, the composition of the underlying evidence base offers useful perspective on how the association was detected. Several of the included studies focused on university students, a population in which sleep paralysis is consistently reported at elevated rates, while others examined clinical groups such as outpatients with panic attacks or anxiety disorders. Work among Egyptian college students, for example, linked sleep paralysis to trait anxiety, pathological worry, and post-traumatic stress symptoms, and a survey of Polish students identified comparable psychological risk factors. Studies of African American samples with panic disorder contributed some of the earliest systematic documentation of isolated sleep paralysis in psychiatric settings, and a large international survey has since catalogued the clinical features and coping strategies people use to disrupt episodes, such as attempting small movements or focusing on breathing.

The measurement instruments themselves matter for interpretation. Because sleep paralysis is typically ascertained through retrospective self-report questionnaires rather than overnight laboratory recording, reported prevalence can vary with how questions are framed and how vividly episodes are remembered. One case-control study that did use polysomnography found objective differences in REM sleep characteristics among people with recurrent isolated sleep paralysis, lending physiological credibility to accounts that might otherwise be dismissed as exaggerated. Standardized tools such as the Unusual Sleep Experiences Questionnaire have been developed specifically to capture the phenomenology of these episodes, separating paralysis from the hallucinatory and fear components that often dominate the experience.

For future research, the authors’ findings point toward longitudinal designs that can disentangle temporal ordering, as well as interventions that target both sleep continuity and anxiety. If disrupted or irregular sleep increases the likelihood of REM intrusions, then trials testing whether anxiety treatment reduces episode frequency would provide a direct test of the mechanistic pathway suggested by this meta-analysis.

Subject of Research: The association between sleep paralysis and anxiety examined through a systematic review and meta-analysis

Article Title: Association between sleep paralysis and anxiety: a systematic review and meta-analysis

Article References: Garrido, G., Donato, K., Gonzalez, J. V., Brito, G. N. E., Romeo, B., Machado, V., Guimarães Lopes, L., & Salles, C. (2026). Association between sleep paralysis and anxiety: a systematic review and meta-analysis. Journal of Clinical Sleep Medicine, 22(1), Article 165. https://doi.org/10.1007/s44470-026-00190-9

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00190-9

Keywords: sleep paralysis, anxiety, anxiety disorders, meta-analysis, systematic review, REM sleep, parasomnia, sleep disorders, mental health, sleep medicine, sleep-wake transition, anxiety symptoms